Anemia and outcomes following left ventricular assist device implantation
Imamura T, Narang N, Besser S, et al. Anemia and Outcomes Following Left Ventricular Assist Device implantation [published online ahead of print, 2022 Mar 1]. Artif Organs. 2022;10.1111/aor.14224. doi:10.1111/aor.14224
BACKGROUND: Patients with concomitant anemia and congestive heart failure have poor outcomes. The prevalence and clinical risk of anemia in patients receiving durable left ventricular assist devices (LVAD) remain unknown. METHODS: We retrospectively analyzed patients who underwent LVAD implantation between 2014 and 2018. The association between hemoglobin level at the time of index discharge and the one-year composite endpoint of heart failure readmissions or hemocompatibility-related adverse events was investigated. RESULTS: A total of 168 patients (57 [48, 66] years old, 123 males) were included and stratified into a classification of anemia (hemoglobin <9.7 g/dL, N = 99) or non-anemia (N = 69). The anemia group had a higher one-year incidence of the composite endpoint (56% versus 36%, p = 0.013) with an adjusted hazard ratio of 1.83 (95% confidence interval 1.08-2.82). Patients with anemia also experienced suboptimal bi-ventricular unloading. CONCLUSIONS: Anemia was prevalent in LVAD patients and associated with a greater risk of heart failure and hemocompatibility-related adverse events. The optimal threshold for therapeutic intervention in response to post-LVAD anemia needs further investigation.